Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/3TC versus standard triple antiretroviral therapy for maintenance treatment in children with HIV
ISRCTN17157458Phase 3Active, not recruiting
- Sponsor
- Penta Foundation
- Start
- Apr 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Standard-of-care with DTG/3TC (2 arms). Primary endpoint: Confirmed viral rebound through week 96. Started Apr 2021; status: active, not recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN17157458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17157458.